Navigation Links
Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
Date:1/24/2012

CULVER CITY, Calif., Jan. 24, 2012 /PRNewswire/ -- Sofie Biosciences, Inc., offering a comprehensive range of products from pre-clinical PET imaging systems to new PET molecular imaging probes to better understand human disease, has been told that a U.S. Patent (8,101,740) will be granted by the United States Patent Office on technology that has been exclusively licensed to Sofie. The patent covers a family of novel PET probes, known as [18F]FAC.

Positron Emission Tomography (PET) is a molecular imaging technology that utilizes minute amounts of labeled molecules ("probes") to target and measure biological and pharmacological processes. Basic scientists can use the same probes to examine cells and mice, as physicians do in patients to visualize and characterize the biology of disease, monitor its progression, and evaluate therapeutic efficacy.

Basic and clinical scientists at UCLA invented this novel PET probe, [18F]FAC, which was created by a slight modification of the drug molecule, gemcitabine, one of the most common drugs for cancer.  Cancer cells lack the normal checks and balances to limit cell growth.  [18F]FAC provides an in vivo imaging assay of cell growth known as the DNA salvage pathway.  Tumors use the salvage pathway to provide high rates of DNA replication for their uncontrolled growth of cells containing malignant instructions.

[18F]FAC measures the enzyme, dCK, which controls the rate of DNA production through the salvage pathway. Cancer drugs like gemcitabine use dCK to convert the drug into a pharmacologically active product that blocks the high rates of DNA replication for growth of malignant cells, and induces DNA damage in cancer cells. One of Sofie's objectives with [18F]FAC is to use PET imaging to allow physicians the means to search throughout the body for tumors that will respond to drugs that target dCK (like gemcitabine and other drugs), thus enabling more patient-specific treatment selecti
'/>"/>

SOURCE Sofie Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sofie Biosciences is Awarded a DOE Phase I SBIR to Commercialize Microscale Radiochemistry Platform
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Milestone Biosciences, LLC Further Strengthens Executive Management Team
6. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
7. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
8. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
9. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
10. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
11. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 , ... part) in, into or from any jurisdiction where to do ... such jurisdiction.  Shire plc ("Shire" or the "Company") ... article this afternoon.  Shire confirms it has held a meeting ... made by Shire without the prior agreement or approval of ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... TECHNOLOGY: GLOBAL MARKETS , the global market for digital ... in 2013. This is estimated to grow to $490 ... rate (CAGR) of 28.6%. , New digital PCR technology ... within the broader PCR field. The opportunities presented by ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/11/2014)... Scottsdale, AZ (PRWEB) July 11, 2014 ... medicine device company specializing in the soft tissue ... SureLock All-Suture Anchor System for surgeries involving the ... predictable fixation through a novel, inserter-controlled deployment method. ... lead to partial deployment, anchor pull-out, or anchor ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... Enrollment in First Cohort --, SAN DIEGO, ... today announced that the Company,has completed enrollment of ... trial,to assess the safety and tolerability of new ... The trial is expected to dose up to ...
... (OTC Bulletin Board: NILT.OB), a biopharmaceutical company focused ... Mr.,Pedro Granadillo was appointed on October 16, 2007 ... is a highly-respected pharmaceutical industry,leader with over 30 ... and quality assurance. "We are pleased to ...
... AMICAS, Inc. (Nasdaq: AMCS ),a leader in radiology ... will present to and meet with investors at,the CIBC ... New,York. (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ), WHEN: ... begins promptly at 10:20 a.m. (Eastern Time), 9:20 a.m. ...
Cached Biology Technology:Nventa updates progress of cervical dysplasia trial with new HspE7 2Nventa updates progress of cervical dysplasia trial with new HspE7 3Nventa updates progress of cervical dysplasia trial with new HspE7 4Nventa updates progress of cervical dysplasia trial with new HspE7 5Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 2Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 3
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/11/2014)... that under the normal circumstances, astrocytes participate ... neuronal environment, and exhibit therapeutic and repairing ... Previous studies have found that nerve cells ... induction have reduced viability, which produces influences ... Yuan, Kailuan General Hospital, Hebei United University, ...
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2Blame it on the astrocytes 2
... Energy,s Brookhaven National Laboratory have identified two promising candidates ... cause of ailments ranging from colds to gastrointestinal disorders ... Letters , a journal of the Federation of European ... of compounds to determine which might block the effects ...
... in metabolic pathways as a result of oncogenes that ... 2) works as a "master gene" that turns on ... to protect the lungs from variety of air pollutants ... at the Johns Hopkins Bloomberg School of Public Health ...
... CATransport proteins are responsible for moving materials such as ... which seals and protects all living cells, to the ... be used to fuel growth or to respond to ... cell. Measuring the activity of transporter proteins in a ...
Cached Biology News:Scientists identify promising antiviral compounds 2Scientists identify promising antiviral compounds 3Hijacking stress response in cancer 2Breakthrough: Sensors monitor cells at work 2
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Human FADD Affinity Purified Polyclonal Ab...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: